Healwell AI Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Healwell AI (TSE:AIDX) Full Year 2024 Results

Key Financial Results

• Revenue: CA$39.0m (up 433% from FY 2023).
• Net loss: CA$25.4m (loss narrowed by 21% from FY 2023).
• CA$0.19 loss per share (improved from CA$0.56 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Healwell AI Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 5.6%.

The primary driver behind last 12 months revenue was the Clinical Research and Patient Services segment contributing a total revenue of CA$19.3m (49% of total revenue). Notably, cost of sales worth CA$21.7m amounted to 56% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CA$42.7m (84% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CA$8.15m. Explore how AIDX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Canada.

Performance of the Canadian Healthcare industry.

The company's shares are down 10% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Healwell AI that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.